 |
|
 |
Production / Manufacturing |
|
|
Operating Tools For Transgenic Manufacturing
Publication Date January 2004
Publisher CredoLegal
Product Type Brief
Pages 19
ISBN Number not applicable
Product Code CRE004
|
|
|
Summary
Transgenic manufacturers are offering manufacturing capabilities to companies with proprietary therapeutic proteins such as monoclonal antibodies. However, these companies themselves often lack several functions required to achieve their commercial objectives, including in-house purification, scale-up, formulation and manufacturing facilities, capital, and the experience to commercialize therapeutic proteins. These capabilities are crucial for value creation and capture. In the longer term, the ability to manufacture commercial scale quantities of purified protein, with access to downstream commercialization, will have a material effect on overall enterprise values.
Collaboration agreements are the only route to technology demonstration, higher margins and, in some cases, royalties, all of which are key value drivers of transgenic manufacturers’ overall business models. Our suggestions for partnering strategies include the several factors, which are evaluated in detailed level in the analysis.
These critical factors include:
- Identification of companies with the most potential drug targets, therapeutic proteins and diagnostics, for which transgenic technology will provide competitive advantage.
- Commercialization of transgenic plant or animal-based protein production technology through collaboration with, top-tier drug discovery and pharmaceutical companies that own a good track record.
- Taking advantage of changes in the marketplace at a later stage and use of bargaining power to gain revenues from several revenue lines simultaneously..
- Use of variable royalty rates as an innovative incentive for your co-operation partner..
- Filling of the possible competence gap by investing in own purification capacity to potentiate large-scale commercial sales and by finding a skilled partner that produces formulated proteins for clinical and commercial sales.
- Seek for alternative market opportunities in order to reduce development risks.
Operating tools for transgenic manufacturers is business intelligence analysis, which contains key industry recommendations for transgenic manufacturers, gives strategic advices for responding to the gaps identified by the manufacturing industry and identifies factors that can be used to find the right long-term manufacturing strategy. By reading the analysis you are able to adapt and tailor your solution portfolios and marketing communications to capitalize on the demands and nuances of each pharmaceutical sub-sector.
|
Content
Chapter 1. Key industry recommendations
Chapter 2. The therapeutic protein manufacturing market and responding to the gaps identified by the manufacturing industry
Chapter 2.1. Closing the gap perceived by the therapeutic manufacturing industry
Chapter 2.2. Closing the gap - portfolio management, finding the right manufacturing strategy
Chapter 2.2.1. Non-therapeutic or mixed-therapeutic manufacturing strategy
Chapter 2.2.2. Generic therapeutic manufacturing strategy
Chapter 2.2.3. Improved performance generics manufacturing strategy
Chapter 3. Mainstream market
Table I. Royalty rates in relation to sales levels (X = base case royalty)
Table II. Biopharmaceutical drugs going off patent
|
|
|
